Last reviewed · How we verify
BNT317 DL2
At a glance
| Generic name | BNT317 DL2 |
|---|---|
| Sponsor | BioNTech SE |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |